Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Admilparant · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Part 1: Treatment A | EXPERIMENTAL | - |
| Part 1: Treatment B | EXPERIMENTAL | - |
| Part 2: Treatment C | EXPERIMENTAL | - |
| Part 2: Treatment D | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Admilparant | DRUG | Specified dose on specified days |
Inclusion Criteria * Participants must have a body mass index (BMI) of 18.0 kg/m2 to 32.0 kg/m2, inclusive, at screening. * Participants must have a body weight of ≥ 50 kg for males and ≥ 45 kg for females at screening. Exclusion Criteria * Participants must not have any significant medical condi...
Admilparant is an investigational small molecule being studied in healthy participants. It is currently in Phase 1 clinical development, with a completed trial assessing the effect of food on its drug levels. It is not approved for any medical condition.
Admilparant is being developed by Bristol-Myers Squibb Company, traded on the New York Stock Exchange under the ticker BMY. The company is conducting clinical trials to evaluate the drug's pharmacokinetics in healthy volunteers.
Admilparant is in Phase 1 clinical development. A single Phase 1 trial has been completed, which studied the effect of food on the drug's levels in healthy participants. The drug remains investigational and has not been approved by regulatory authorities.
Admilparant has one completed Phase 1 trial, NCT07225647, titled "A Study to Assess the Effect of Food on the Drug Levels of Admilparant." The trial enrolled 56 healthy participants in the United States, with ages starting at 18 years, and included both sexes.
No, Admilparant is not FDA approved. It is an investigational drug currently in Phase 1 clinical development. The completed trial focused on healthy participants to assess how food affects the drug's levels, which is part of early-stage pharmacokinetic evaluation.